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Background: Some, but not all, epidemiologic evidence supports a role for cholesterol, the 
precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic 
mouse model of prostate cancer, we tested the effect of modifying serum cholesterol levels on 
prostate tumor development and growth. We hypothesized that serum cholesterol reduction 
would lower tumor androgens and slow prostate cancer growth. 
Methods: PTENloxP/loxP-Cre+ mice consuming ad libitum high fat, high cholesterol diets (40% fat, 
1.25% cholesterol) were randomized after weaning to receive the cholesterol uptake inhibitor, 
ezetimibe (Zetia; 30 mg/kg diet), or no intervention, and sacrificed at 2, 3 or 4 months of age. 
Serum cholesterol and testosterone were measured by ELISA and intraprostatic androgens by 
mass spectrometry. Prostate histology was graded, and proliferation and apoptosis in tumor 
epithelium and stroma was assessed by Ki67 and TUNEL, respectively.  
Results: Zetia-treated mice had lower serum cholesterol at 4 months (p=0.031). Serum 
cholesterol was positively correlated with prostate weight (p=0.033) and tumor epithelial 
proliferation (p=0.069), and negatively correlated with tumor epithelial apoptosis (p=0.004), but 
unrelated to body weight (p=0.195). Tumor stromal cell proliferation was reduced in the Zetia 
group (p=0.010). Increased serum cholesterol at 4 months was associated with elevated 
intraprostatic DHEA, testosterone and androstenedione (p=0.043, p=0.074, p=0.031, 
respectively). However, cholesterol lowering did not significantly affect adenocarcinoma 
development at 2, 3 or 4 months of age (0%, 78%, 100% in Zetia-treated vs. 0%, 80%, 100% in 
mice not receiving Zetia).  
Conclusions: Though serum cholesterol reduction did not significantly affect the rate of 
adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer, it 
lowered intraprostatic androgens and slowed tumor growth. These findings support a role for 
4 
 
serum cholesterol in promoting prostate cancer growth, potentially via enhanced tumor 
androgen signaling, and may provide new insight into cholesterol-lowering interventions for 




Obesity is associated with increased risk of aggressive prostate cancer and elevated prostate 
cancer-specific mortality.1 Currently, it is estimated that one in five US adults have uncontrolled 
hypercholesterolemia, a metabolic disorder associated with obesity.2 While some epidemiologic 
evidence supports an association between hypercholesterolemia and increased incidence of 
aggressive prostate cancer,3-6 a recent meta-analysis found no significant association between 
serum cholesterol and either overall or high-grade disease.7 Several studies reported positive 
associations between hypercholesterolemia and increased risk of prostate cancer recurrence8,9 
and mortality,10 yet others found no associations or even inverse relationships.11,12 Statins, a 
group of widely-prescribed cholesterol-lowering drugs, are associated with lower risk of 
aggressive prostate cancer,13 decreased prostate cancer recurrence14 and reduced mortality.15 
However, it is not clear whether this effect is due to direct effects of the statin itself, or indirect 
effects mediated via cholesterol-lowering.16 As such, the true biological potential of targeting 
serum cholesterol to slow prostate cancer growth and progression is promising, but unclear.  
Cholesterol is the precursor for de novo steroidogenesis, which is crucial for prostate cancer 
growth.17 Indeed, serum cholesterol reduction has been demonstrated to lower intratumoral 
androgen levels and slow tumor growth in a xenograft mouse model of human prostate 
cancer.18,19 However, the effect of cholesterol reduction on prostate cancer growth has never 
been tested in a transgenic model, which enables assessment of tumor growth within the native 
prostate microenvironment. The objective of this study was to determine the effect of modifying 
serum cholesterol levels on tumor development and growth in an obese transgenic mouse 
model of prostate cancer. Given that PTEN is among the most frequently mutated/deleted 
genes in human prostate cancer,20 we selected the PTEN-null mouse model for this study. We 
hypothesized that reduction of serum cholesterol levels would lower tumor androgens and slow 
tumor growth.  
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Materials and Methods 
Animal study design 
All animal protocols were approved by Duke University Institutional Animal Care and Use 
Committee. Prostate-specific homozygous deletion of PTEN was achieved by crossing 
PTENloxp/loxp mice with mice of the ARR2Probasin-cre transgenic line PB-Cre4, where Cre 
recombinase is under the control of a modified rat prostate-specific probasin promoter, as 
previously reported.20 Tumor development is well characterized in this mouse model, with 
development of prostatic hyperplasia by 4 weeks of age, mouse prostate intraepithelial 
neoplasia (mPIN) by 6 weeks of age, and invasive prostate adenocarcinoma by 9 weeks of 
age.20 Breeding pairs were obtained from the National Institutes of Health Mutant Mouse 
Resource and Research Center (NIH MMRRC) on a C57BL/6 genetic background and 
PTENloxp/loxp-Cre+ (PTEN-null) mice were bred in-house. Diets were prepared by Research Diets 
Inc. (New Brunswick, NJ), and sterilized by irradiation. At approximately 30 days of age, 92 
male PTEN-null mice were randomized to receive a) ad libitum high-fat high-cholesterol (HFHC, 
n=45; 40 kcal% fat, 43 kcal% carbohydrate, 17 kcal% protein, 1.25% cholesterol) or b) ad 
libitum HFHC diet with ezetimibe, a cholesterol uptake inhibitor (Zetia, n=47; HFHC + 30 mg/kg 
ezetimibe; Supplementary Table S1). All mice were group-housed, and body mass and average 
food consumption were measured biweekly for the study duration. Mice were euthanized using 
a lethal dose of ketamine and xylazine followed by bilateral thoracotomy at two (n=12 per diet 
group), three (n=10 per diet group) and four months of age (HFHC, n=23 and Zetia, n=25). 
Blood was obtained via cardiac puncture immediately following euthanasia, allowed to clot at 
room temperature for 30 minutes, and centrifuged at 13,000 rpm for 90 seconds. Serum was 
collected and stored at -80°C for analyses. The entire genitourinary (GU) tract was removed 
intact from PTEN mice. Seminal vesicles, bladder and fat were removed, and the prostate was 
weighed and bisected along the sagittal plane. One half of the prostate was flash frozen in liquid 
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nitrogen and stored at -80°C, while the other was fixed in 10% formalin for 48 hours and then 
paraffin embedded. The formalin-fixed prostate was oriented within the paraffin block to ensure 
representation of all prostate lobes (i.e., dorsal, ventral and anterior) on the resulting slides.  
Histologic analyses 
Formalin-fixed paraffin-embedded prostate tissue was cut to generate three 4 µm sections, each 
separated by 50 µm, and stained with hematoxylin and eosin (H&E) for histopathologic 
evaluation. Slides were scanned using an Aperio ScanScope and grading of H&Es was 
conducted by a single investigator (EHA) blinded to dietary group, under the guidance of a 
board-certified pathologist (GVT). All prostate lobes were graded across all three sections, and 
lesions (mPIN, invasive and intracystic adenocarcinoma) were noted as present vs. absent. 
Intracystic lesions were found only in the anterior lobe, while mPIN and invasive 
adenocarcinoma were found in all lobes. 
Serial 4 µm sections were cut and stained with antibodies against Ki67 (Thermo Scientific, 
Rockford, IL) and TUNEL (ApopTag® Plus Peroxidase In Situ Apoptosis Kit; Millipore Inc., 
Billerica, MA) to assess proliferation and apoptosis, respectively, in regions of invasive 
adenocarcinoma across all prostate lobes. These analyses were restricted to mice 4 months of 
age. Ki67 and TUNEL H score was quantified within epithelium and stroma separately using a 
digital pathology nuclear algorithm (Definiens Tissue Studio®) at the Translational Pathology 
Core, University of North Carolina at Chapel Hill. In order to assess these markers in invasive 
adenocarcinoma regions only, areas of normal prostate tissue were manually excluded from 
analysis, and areas of necrosis and cellular debris (including intracystic lesions, where present) 
were excluded using the digital algorithm. As such, in mice with intracystic lesions, invasive 
adenocarcinoma in the area surrounding the intracystic lesion in the anterior lobe, along with 
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invasive adenocarcinoma in ventral and dorsal lobes, was analyzed for Ki67 and TUNEL 
staining.  
Serum and prostate analyses  
All serum parameters were measured at 4 months of age. To assess liver health, we measured 
serum levels of total bilirubin, alanine transaminase (ALT) and aspartate transaminase (AST) 
using ELISA (Sigma Aldrich, St. Louis, MO). Serum cholesterol levels were measured using the 
Infinity Cholesterol Liquid Stable Reagent (Thermo Electron Corp., Waltham, MA) and serum 
testosterone levels were measured by ELISA (R&D systems, Minneapolis, MN). Androgen 
concentrations were measured in flash frozen prostate tissue from 4 month old mice using mass 
spectrometry, as previously described.21 
Statistical analyses 
Differences in body and prostate weights, serum cholesterol levels and tumor proliferative and 
apoptotic indexes between dietary groups were examined using Student’s t tests. Linear 
regression was used to examine the relationship between serum cholesterol levels and body 
and prostate weight, tumor proliferative and apoptotic indexes, and serum and prostate 
androgen levels. Statistical analysis was carried out using STATA 13.0 (Stata, Corp., College 




Effect of serum cholesterol reduction on caloric intake and body weight 
Caloric intake did not differ between dietary groups (Figure 1A), and there were no differences 
in body weights between dietary groups at randomization (HFHC vs. Zetia; 17.3 g vs. 17.6 g, 
p=0.800) or at 4 month sacrifice (HFHC; 36.6 g vs. Zetia; 36.2 g, p=0.767; Figure 1B, C). 
However, inhibition of cholesterol uptake resulted in significantly reduced serum cholesterol 
levels by 4 months of age (Zetia vs. HFHC; 161 mg/dl vs. 201 mg/dl, respectively; p=0.031; 
Figure 1C). Serum cholesterol level was not significantly correlated with body weight at sacrifice 
(Figure 1D). There were no differences between dietary groups with respect to liver and spleen 
size (all p>0.1; Supplementary Figure S1) or liver function (all p>0.1; Supplementary Figure S2).  
Effect of serum cholesterol reduction on prostate tumor development and growth 
Prostate weight was slightly, but not significantly, reduced in the Zetia group (0.39g vs. 0.45g; 
p=0.275; Figure 2A). However, as a continuous variable, higher serum cholesterol was 
significantly positively correlated with larger prostate size (p=0.033; Figure 2B).  
In order to examine the effect of reducing serum cholesterol levels on prostate cancer 
development, we classified prostate histology as normal, mPIN, invasive adenocarcinoma or 
intracystic adenocarcinoma, according to current guidelines.22 By 4 months of age, all mice had 
developed both invasive and intracystic adenocarcinoma (Table 1), regardless of dietary group. 
The rate of development of invasive or intracystic adenocarcinoma did not vary significantly by 
dietary group (Table 1).  
Effect of serum cholesterol on prostate tumor proliferation and apoptosis 
We used an automated digital pathology approach to quantify rates of proliferation and 
apoptosis in the tumor epithelium and tumor stroma separately, excluding areas of normal 
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prostate tissue, necrosis and fluid-filled intracystic lesions (Supplementary Figures S3, S4, S5). 
We found that mice randomized to the Zetia diet had lower tumor epithelial proliferation than 
those randomized to HFHC at 4 months of age (Ki67 H score 19.6 vs. 25.4; p=0.173; Figure 3), 
although this association was not significant. There was no difference in tumor epithelial 
apoptosis scores between dietary groups (p=0.528). When serum cholesterol was examined as 
a continuous variable, there was a positive correlation between high serum cholesterol levels 
and increased tumor epithelial cell proliferation at 4 months (p=0.069), although this was not 
statistically significant, and a negative correlation between high serum cholesterol levels and 
tumor epithelial cell apoptosis (p=0.004; Figure 3). Restricting our analysis to the tumor stroma 
revealed that mice consuming Zetia diet had significantly reduced tumor stromal proliferation 
(p=0.010), although rates of tumor stromal cell apoptosis did not differ between dietary groups 
(p=0.723; Supplementary Figure S6). However, serum cholesterol levels were significantly 
inversely correlated with tumor stromal cell apoptosis at 4 months (p=0.048), although the 
positive correlation between serum cholesterol levels and stromal proliferation was not 
significant (p=0.328; Supplementary Figure S6). We investigated whether serum cholesterol 
levels modified tumor composition by quantifying the proportion of stromal tissue within the 
tumor, and found no significant differences between dietary groups (data not shown). 
Effect of serum cholesterol levels on serum and prostate androgen concentrations 
Levels of serum and prostate androgens did not differ between dietary groups at 4 months of 
age (data not shown). However, levels of prostate testosterone, DHT, DHEA and 
androstenedione were positively correlated with serum cholesterol levels, although these 
associations were not significant (Table 2). Adjusting linear regression analyses for age at 
dietary randomization strengthened these associations, particularly for DHEA and 
androstenedione (p=0.043 and p=0.031, respectively). Serum testosterone levels were 
positively correlated with serum cholesterol levels at 4 months, and this association was 
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strengthened after adjusting for age at dietary randomization (p=0.077; Table 2), though it 




Obesity, a common disorder affecting approximately one third of US men,23 is associated with 
increased incidence of aggressive prostate cancer and elevated prostate cancer mortality.1 
While the association between obesity and prostate cancer is likely multifactorial, epidemiologic 
and preclinical evidence indicates a potential role for high cholesterol, an obesity-associated 
metabolic abnormality, in prostate cancer progression,24 though not all studies have found a link 
between cholesterol and prostate cancer.7 Using an obese PTEN-null transgenic mouse model 
of prostate cancer, we show that lowering serum cholesterol levels reduced tumor proliferation, 
increased tumor apoptosis, lowered tumor androgen concentrations and slowed prostate tumor 
growth. In contrast, we found that serum cholesterol reduction did not significantly affect the rate 
of adenocarcinoma development. Though our findings do not support a role for cholesterol 
lowering in slowing tumor development in the PTEN-null mouse model of prostate cancer, they 
do provide evidence for an effect of serum cholesterol on tumor androgen signaling and tumor 
growth. Future studies are needed to determine the potential role for cholesterol-lowering 
interventions in prostate cancer treatment. 
Since the recognition of prostate cancer as an androgen-dependent disease,25 targeting the 
androgen signaling pathway has been the mainstay of advanced prostate cancer treatment. 
While the disease is initially responsive to androgen-deprivation therapy, the majority of patients 
eventually go on to develop castration-resistant prostate cancer (CRPC), which is currently 
incurable. There is substantial evidence that achieving castrate levels of circulating androgens 
does not eliminate intraprostatic androgens, and that intratumoral de novo androgen synthesis 
from cholesterol may be an important source of these residual tumor androgens in castrate 
men.26,27 Indeed, statin use and lower cholesterol levels have been associated with lower levels 
of PSA,28,29 whose gene is under the control of the androgen receptor, suggesting that 
cholesterol reduction may impact intraprostatic androgen signaling. Furthermore, some 
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epidemiologic evidence supports a potential role for serum cholesterol level in response to 
androgen deprivation therapy. One study reported a shorter time to castrate-resistant prostate 
cancer development in men with elevated serum cholesterol levels at the time of androgen 
deprivation therapy, relative to those with normal cholesterol.30 Another study demonstrated that 
statin use at initiation of androgen deprivation therapy delayed progression to castrate-resistant 
prostate cancer.31 In the present study, we demonstrate that reduction of serum cholesterol 
levels in a mouse model of prostate cancer decreased intratumoral androgen concentrations, 
adding support to epidemiologic and laboratory data that cholesterol-lowering strategies should 
potentially be explored alongside androgen-deprivation therapy in prostate cancer.  
This study should be considered in light of its limitations. Although statins are the most 
commonly prescribed cholesterol-lowering drugs in the clinic, they do not reduce serum 
cholesterol levels in mice.32 As such, we achieved cholesterol reduction in our mouse model 
using the FDA-approved drug, ezetimibe, usually prescribed to human patients in conjunction 
with a statin or as a substitute in patients that cannot tolerate a statin. However, given the 
hepato-selectivity and low systemic bioavailability of statins, it may be that their effects on the 
prostate are predominantly mediated indirectly via reduction of systemic cholesterol levels.33 
Furthermore, the use of ezetimibe in the present study enabled examination of the effect of 
cholesterol reduction on prostate cancer growth in the absence of changes to dietary 
composition and/or obesity status, both of which have been implicated in prostate cancer.1,34 
Future studies should explore the effect of statin use and serum cholesterol reduction on 
intratumoral androgen signaling in humans. Regarding our tumor growth measurements, we 
could not assess the contribution of fluid-filled intracystic lesions to tumor weight, and this may 
bias our results. However, our finding that lowering serum cholesterol slowed tumor growth is 
also supported by our observation of decreased tumor cell proliferation and increased tumor cell 
apoptosis in mice with lower cholesterol levels, as determined by IHC assays. These limitations 
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are balanced by an important strength of this study. Loss of the tumor suppressor, PTEN, is one 
of the most common genetic alterations in prostate cancer,20 making this a relevant mouse 
model with which to study this disease. In addition, the use of a transgenic mouse model 
enabled assessment of the effect of cholesterol reduction on prostate cancer growth within the 
native microenvironment, known to play a role in disease progression.35  
Cardiovascular disease and cancer are leading causes of mortality in Western society,36 and 
prostate cancer is the second most common cause of male cancer deaths in the US.37 
Therefore, understanding the role of hypercholesterolemia as a shared risk factor for these 
diseases has great public health importance. Furthermore, high cholesterol is a readily 
modifiable risk factor through the use of pharmaceutical agents and/or lifestyle modifications. 
Notably, we demonstrate that cholesterol reduction affects prostate cancer growth even within 
the context of diet-induced obesity, a known prostate cancer promoter. Together with 
epidemiologic evidence suggesting a potential role for hypercholesterolemia in promoting 
prostate cancer progression,8,10 and for statins in preventing aggressive prostate cancer 
incidence and progression,13-15 these results support further studies exploring a role for 
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Figure 1: Caloric intake (A) and body weight (B) trajectories throughout the study duration in the 
PTEN-null transgenic mouse model of prostate cancer, median differences in serum cholesterol 
level between dietary groups at 4 months of age (C), and correlation between body weight at 4 
months of age and serum cholesterol levels (D). 
Figure 2: Effect of serum cholesterol reduction on prostate weight at 4 months of age in the 
PTEN-null transgenic mouse model 
Figure 3: Effect of cholesterol reduction on proliferation and apoptosis in prostate tumor 



















































HFHC  0 (0)  1 (14)  7 (78)  4 (44)  23 (100)  23 (100) 






 β coefficient (95% CI)* p value* β coefficient (95% CI)** p value** 
Serum levels         
   Testosterone  0.017 (‐0.022, 0.057)  0.358  0.036 (‐0.005, 0.076)  0.077 
Prostate levels         
   Testosterone 0.020 (‐0.010, 0.050)  0.169  0.027 (‐0.003, 0.058) 0.074 
   DHT 0.007 (‐0.014, 0.029)  0.447  0.013 (‐0.007, 0.033) 0.179 
   DHEA 0.003 (‐0.001, 0.007)  0.165  0.004 (0.000, 0.008) 0.043 
   
Androstendione 0.001 (‐0.0002, 0.003)  0.095  0.002 (0.0002, 0.0034) 0.031 
DHEA; dehydroepiandrosterone, DHT; dihydrotestosterone 
P values obtained by linear regression 
*unadjusted 
**adjusted for age at dietary randomization   
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Supplementary Data 
Supplementary Table S1: Formulation of diets used in the current study 
Research Diets Formula 
High fat high cholesterol 
(HFHC), D09062501 
High fat high cholesterol + Zetia 
(Zetia), D09062502 
  g% (kcal%) 
Protein  20 (17)  20 (17) 
Carbohydrate  49 (43)  49 (43) 
Fat  21 (40)  21 (40) 
     
kcal/g  4.6  4.6 
  g  
Casein  195  195 
DL‐Methionine  3  3 
Corn starch  50  50 
Maltodextrin 10  100  100 
Sucrose  341  341 
Cellulose, BW200  50  50 
Milk fat  200  200 
Corn oil  10  10 
Mineral Mix S10001  35  35 
Calcium Carbonate  4  4 
Vitamin Mix V10001  10  10 
Choline Bitartrate  2  2 
Cholesterol  12.05  12.05 
Ethoxyquin  0.04  0.04 
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FD&C Red Dye #40  0  0.05 
FD&C Yellow Dye #5  0.05  0 
Total  1012.14  1012.14 
Cholesterol (%)  1.25  1.25 
Ezetimibe (mg/kg)  0  30 
 
 
 
Supplementary Figure S1: Effect of serum cholesterol reduction on liver and spleen size at 4 months of 
age in the PTEN‐null transgenic mouse model 
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Supplementary Figure S2: Effect of serum cholesterol reduction on liver function at 4 months of age in 
the PTEN‐null transgenic mouse model 
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Supplementary Figure S3: Definiens Tissue Studio algorithm to separate epithelium from stroma 
Legend: Prostate gland stained for TUNEL (A), and processed by Aperio algorithm to differentiate tissue 
types (B); Red=epithelium; dark blue=necrosis; light blue=stroma; yellow=glass; grey=area manually 
excluded from analysis 
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Supplementary Figure S4: Quantification of tumor epithelial staining using Definiens Tissue Studio 
Legend: Blue=negative nuclei; Yellow/Orange/Red=positive nuclei with increasing staining intensity 
Note exclusion of stromal and necrotic areas of tissue by the algorithm 
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Supplementary Figure S5: Representative images of low and high Ki67 staining (A and B, respectively) 
and low and high TUNEL staining (C and D, respectively) at 4 months of age in the PTEN‐null transgenic 
mouse model   
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 Supplementary Figure S6: Effect of cholesterol reduction on proliferation and apoptosis in prostate 
tumor stroma at 4 months of age in the PTEN‐null transgenic mouse model 
 
 
